Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stereotactic Intracerebral Injection of Autologous Induced Pluripotent Stem Cell-derived Dopamine Progenitor Cells in Patients with Parkinson's Disease

NCT06821529 is registered in ClinicalTrials.gov with iCamuno Biotherapeutics Ltd. as lead sponsor.

NCT NCT06821529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06821529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stereotactic Intracerebral Injection of Autologous Induced Pluripotent Stem Cell-derived Dopamine Progenitor Cells in Patients with Parkinson's Disease
Lead sponsor
iCamuno Biotherapeutics Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
May 15, 2025
Completion date
September 30, 2026
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease